FDA Approves Atezolizumab / Tecentriq Hybreza™️ For Subcutaneous PD-L1 Cancer Immunotherapy in NSCLC

Dr. Horn on the FDA Approval of Atezolizumab Plus Bevacizumab and Chemotherapy in NSCLCПодробнее

Sangeetha Palakurthi on FDA Approval of Atezolizumab in NSCLCПодробнее

Dr. Mittendorf Highlights FDA Approval of Atezolizumab/Nab-Paclitaxel in PD-L1+ TNBCПодробнее

Dr. Wakelee on BIRCH Trial for Atezolizumab in Patients With NSCLCПодробнее

Best Results Ever in the Treatment of Small Cell Lung Cancer: Immunotherapy in Primary CareПодробнее

Dr. Melissa Johnson on Atezolizumab in Patients With NSCLCПодробнее

Tecentriq Approval in NSCLC ‘Stops the Brakes’ on PD-L1 ExpressionПодробнее

FDA Approval of Atezolizumab for NSCLCПодробнее

FDA D.I.S.C.O. Burst Edition: FDA approval of Tecentriq (atezolizumab) for adjuvant treatment fol...Подробнее

Tecentriq (atezolizumab)- Non-Small Cell Lung Cancer (NSCLC)Подробнее

Copy of Dr. Hamilton on FDA Approval of Atezolizumab/Nab-Paclitaxel in TNBCПодробнее

First-line atezolizumab plus chemotherapy improves survival in lung cancer patientsПодробнее

FDA D.I.S.C.O. Burst Edition: FDA approvals of Tecentriq (atezolizumab) for unresectable or metas...Подробнее

Fastest Cancer drug, very easy to administer, reduced discomfort, and shorten duration of treatmentПодробнее

Dr. Steinberg on the FDA Approval of Atezolizumab in Bladder CancerПодробнее

Combining Immunotherapy and Chemotherapy in Patients With SCLCПодробнее

The FDA Approval of Atezolizumab in Bladder CancerПодробнее

FDA approves Atezolizumab as Adjuvant Treatment for Non-small Cell Lung CancerПодробнее